Special Issue "Novel Therapeutic Approaches for Pulmonary Arterial Hypertension"

A special issue of Journal of Clinical Medicine (ISSN 2077-0383).

Deadline for manuscript submissions: closed (31 January 2017).

Special Issue Editor

Assoc. Prof. Jane A. Leopold
E-Mail Website
Guest Editor
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
Interests: pulmonary hypertension

Special Issue Information

Dear Colleagues,

Pulmonary arterial hypertension (PAH) is a life-threatening cardiopulmonary disease that is characterized by hypertrophic vascular remodeling of small distal pulmonary arteries with near obliteration of the vessel lumen, increased pulmonary vascular resistance, and pulmonary artery hypertensive pressures. These adverse hemodynamic parameters affect right ventricular-pulmonary artery coupling and ultimately lead to right ventricular failure and premature death. Advances have been made in contemporary pharmacotherapies with combination drugs, including agents that target the nitric oxide, prostacyclin, and endothelin signaling pathways. Despite this, patients continue to have progression of disease with adverse clinical events and outcomes. This has led to the search for novel and innovative therapeutic interventions to target the pulmonary vasculature, the right ventricle or both. Studies to identify novel disease mediators have become a priority and include next generation genetic sequencing, metabolomic profiling, and proteomic analyses. Other advances in the field involve utilizing data from these studies for gene therapies that can be delivered using aerosol, intravenous, or intracoronary delivery approaches. Cell therapy has been another area of active interest, especially with respect to treating the right ventricle. Other therapy in the early days of investigation is pulmonary artery denervation, which denervates the large pulmonary arteries to decrease sympathetic tone and, thereby, promote vasorelaxation. Together these and other novel therapies will advance the field and modify the pulmonary vascular and right ventricular disease pathophenotype to improve clinical outcomes.

Assoc. Prof. Jane A. Leopold
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Pulmonary arterial hypertension
  • Right ventricular dysfunction
  • Whole genome sequencing/whole exome sequencing
  • Metabolomic profiling and metabolic modulators
  • Proteomic analysis
  • Gene therapy
  • Cell therapy
  • Chemotherapeutic agents
  • Pulmonary artery denervation

Published Papers (4 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Review

Open AccessReview
Nanoparticle-Mediated Drug Delivery System for Pulmonary Arterial Hypertension
J. Clin. Med. 2017, 6(5), 48; https://doi.org/10.3390/jcm6050048 - 29 Apr 2017
Cited by 7
Abstract
Nanoparticles have been used as a novel drug delivery system. Drug-incorporated nanoparticles for local delivery might optimize the efficacy and minimize the side effects of drugs. The efficacy and safety of intratracheal administration of prostacyclin analog (beraprost) -incorporated nanoparticles and imatinib (a PDGF-receptor [...] Read more.
Nanoparticles have been used as a novel drug delivery system. Drug-incorporated nanoparticles for local delivery might optimize the efficacy and minimize the side effects of drugs. The efficacy and safety of intratracheal administration of prostacyclin analog (beraprost) -incorporated nanoparticles and imatinib (a PDGF-receptor tyrosine kinase inhibitor) -incorporated nanoparticles in Sugen-hypoxia-normoxia or monocrotaline rat models of pulmonary arterial hypertension (PAH) and in human PAH-pulmonary arterial smooth muscle cells have been reported. The use of inhaled drug-incorporated nanoparticles might be a novel approach for the treatment of PAH. Full article
(This article belongs to the Special Issue Novel Therapeutic Approaches for Pulmonary Arterial Hypertension)
Show Figures

Figure 1

Open AccessFeature PaperReview
Emerging Metabolic Therapies in Pulmonary Arterial Hypertension
J. Clin. Med. 2017, 6(4), 43; https://doi.org/10.3390/jcm6040043 - 04 Apr 2017
Cited by 16
Abstract
Pulmonary hypertension (PH) is an enigmatic vascular disorder characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance, ultimately resulting in pressure overload, dysfunction, and failure of the right ventricle. Current medications for PH do not reverse or prevent disease progression, and current [...] Read more.
Pulmonary hypertension (PH) is an enigmatic vascular disorder characterized by pulmonary vascular remodeling and increased pulmonary vascular resistance, ultimately resulting in pressure overload, dysfunction, and failure of the right ventricle. Current medications for PH do not reverse or prevent disease progression, and current diagnostic strategies are suboptimal for detecting early-stage disease. Thus, there is a substantial need to develop new diagnostics and therapies that target the molecular origins of PH. Emerging investigations have defined metabolic aberrations as fundamental and early components of disease manifestation in both pulmonary vasculature and the right ventricle. As such, the elucidation of metabolic dysregulation in pulmonary hypertension allows for greater therapeutic insight into preventing, halting, or even reversing disease progression. This review will aim to discuss (1) the reprogramming and dysregulation of metabolic pathways in pulmonary hypertension; (2) the emerging therapeutic interventions targeting these metabolic pathways; and (3) further innovation needed to overcome barriers in the treatment of this devastating disease. Full article
(This article belongs to the Special Issue Novel Therapeutic Approaches for Pulmonary Arterial Hypertension)
Show Figures

Graphical abstract

Open AccessFeature PaperReview
The Changing Landscape of Pulmonary Arterial Hypertension in the Adult with Congenital Heart Disease
J. Clin. Med. 2017, 6(4), 40; https://doi.org/10.3390/jcm6040040 - 30 Mar 2017
Cited by 6
Abstract
Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a common type of pulmonary arterial hypertension (PAH) and a frequent complication of congenital heart disease (CHD). PAH-CHD represents a heterogeneous patient population and it is important to distinguish between the underlying cardiac [...] Read more.
Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a common type of pulmonary arterial hypertension (PAH) and a frequent complication of congenital heart disease (CHD). PAH-CHD represents a heterogeneous patient population and it is important to distinguish between the underlying cardiac defects considering the prognostic and therapeutic implications. Improved interventional techniques have enabled repair or palliation of most cardiac defects, though a substantial number of patients remain at high risk for PAH after closure. Traditionally, the treatment and management of PAH-CHD patients has been limited to palliative and supportive care, and based on expert opinion rather than clinical trials. Recently, however, the availability of advanced PAH-specific treatment has opened up a new field for the clinical management of this condition. Nevertheless, there is limited evidence on the optimal therapeutic approach for PAH-CHD. Herein, we discuss the current and novel therapeutic options for PAH-CHD as well as highlight several challenges in the clinical management at present. Full article
(This article belongs to the Special Issue Novel Therapeutic Approaches for Pulmonary Arterial Hypertension)
Show Figures

Figure 1

Open AccessReview
A Review of Targeted Pulmonary Arterial Hypertension-Specific Pharmacotherapy
J. Clin. Med. 2016, 5(12), 114; https://doi.org/10.3390/jcm5120114 - 06 Dec 2016
Cited by 6
Abstract
Significant advances in the understanding of the pathophysiology of pulmonary arterial hypertension over the past two decades have led to the development of targeted therapies and improved patient outcomes. Currently, a broad armamentarium of pulmonary arterial hypertension-specific drugs exists to assist in the [...] Read more.
Significant advances in the understanding of the pathophysiology of pulmonary arterial hypertension over the past two decades have led to the development of targeted therapies and improved patient outcomes. Currently, a broad armamentarium of pulmonary arterial hypertension-specific drugs exists to assist in the treatment of this complex disease state. In this manuscript, we provide a comprehensive review of the current Food and Drug Administration (FDA)-approved pulmonary arterial hypertension-specific therapies, and their supporting evidence for adults, targeting the nitric oxide, soluble guanylate cyclase, endothelin, and prostacyclin pathways. Full article
(This article belongs to the Special Issue Novel Therapeutic Approaches for Pulmonary Arterial Hypertension)
Back to TopTop